Comparative Pharmacology
Head-to-head clinical analysis: GYNOREST versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNOREST versus NORLUTATE.
GYNOREST vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category C
Category C
Progestin
Progestin